NFE2L2 and pancreatic intraductal papillary-mucinous neoplasm: Although future studies are required to examine whether the dose and duration of ROS perturbation might affect IPMN incidence, our current observation suggests that alternative NRF2-regulated pathways drive its tumor-suppressive function in IPMN.